10-Q: NovelStem International Corp. Reports Second Quarter 2024 Results Amidst Going Concern Uncertainty

NovelStem International Corp. reported a net loss of $605,905 for the six months ended June 30, 2024, and faces substantial doubt about its ability to continue as a going concern.

Summary

• NovelStem International Corp., a holding company with investments in biotech and media, reported a net loss of $605,905 for the six months ended June 30, 2024, compared to a net loss of $3,143,581 for the same period in 2023.
• The company's primary assets are a 30.51% equity interest in NewStem Ltd, a biotech company, and a 50% equity interest in NetCo Partners, a media business.
• The company's accumulated deficit is approximately $294,000,000, with $7,050,000 of that accumulated since the business focus shift in 2018.
• The company's current assets were $28,760 and current liabilities were $3,515,530 as of June 30, 2024.
• The company has secured financing agreements totaling $1,750,000 to fund operations through November 2024, but will need additional funds to continue operations for the next 12 months.
• The company's ability to continue as a going concern is dependent on additional fundraising, financing, or monetizing its investment in NetCo, as well as NewStem's ability to become profitable.
• The company's investment in NewStem is carried at $1,678,991, while its investment in NetCo is carried at $130,789 as of June 30, 2024.
• The company's share of the net loss of NewStem was $105,243 for the six months ended June 30, 2024.
• The company's share of the net loss of NetCo was $2,920 for the six months ended June 30, 2024.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a large accumulated deficit, going concern uncertainty, and a material weakness in internal controls. While there are some positive aspects, such as reduced losses compared to the previous year, the overall sentiment is negative due to the company's precarious financial position and operational risks.

Positives

• The net loss for the six months ended June 30, 2024, was significantly lower than the same period in 2023, indicating improved financial performance.
• The company secured $1,750,000 in financing agreements to fund operations through November 2024.
• The company recognized a gain on derivative financial instruments of $25,000 during the six months ended June 30, 2024.

Negatives

• The company has an accumulated deficit of approximately $294,000,000.
• The company's current liabilities significantly exceed its current assets, raising concerns about short-term financial stability.
• The company's ability to continue as a going concern is dependent on additional fundraising, financing, or monetizing its investment in NetCo, as well as NewStem's ability to become profitable.
• The company's investment in NewStem is carried at $1,678,991, while its investment in NetCo is carried at $130,789 as of June 30, 2024.
• The company's share of the net loss of NewStem was $105,243 for the six months ended June 30, 2024.
• The company's share of the net loss of NetCo was $2,920 for the six months ended June 30, 2024.
• The company's interest expense increased to $201,406 for the six months ended June 30, 2024, due to increased debt.
• The company has a note receivable from NewStem of $500,000 related to a potential acquisition that was not consummated.

Risks

• The company's ability to continue as a going concern is uncertain and dependent on securing additional funding and NewStem's profitability.
• The company has a significant accumulated deficit and negative shareholders' equity.
• The company's current liabilities significantly exceed its current assets, indicating potential liquidity issues.
• The company's investment in NewStem is subject to impairment risk.
• The company's litigation funding agreement has resulted in a significant liability.
• The company's internal controls over financial reporting have been identified as a material weakness.
• The company's potential acquisition of NewStem was not consummated, and the company is in default of the purchase agreement.

Future Outlook

The company expects to continue to incur greater expenses as it expands its business, including funding NewStem, or enters into strategic partnerships. The company will need to obtain additional funds to continue its operations and is pursuing additional financing and fundraising until its equity investment in NewStem is profitable.

Management Comments

• Management plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable.
• Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will be able to continue as a going concern and become profitable.

Industry Context

The company operates in the biotech and media industries, both of which are highly competitive and subject to rapid technological and market changes. The company's success is dependent on the ability of NewStem to develop and commercialize its products and the ability of NetCo to monetize its intellectual property.

Comparison to Industry Standards

• NovelStem's financial performance is significantly weaker than many established biotech companies, which typically have higher revenue and lower losses.
• The company's reliance on debt financing and the uncertainty surrounding its going concern status are not typical of well-established companies in the biotech or media sectors.
• The company's litigation funding agreement is a unique situation that is not common among its peers.
• The company's internal control weaknesses are a concern and are not typical of well-managed public companies.
• Compared to companies like Moderna or BioNTech, which have successfully commercialized products, NovelStem is still in the early stages of development and faces significant challenges.
• Compared to media companies like Disney or Netflix, NetCo's revenue is minimal and its ability to monetize its intellectual property is uncertain.

Legal Proceedings

• The company was involved in an arbitration proceeding against their 50% partner in NetCo, which concluded with a partially favorable outcome for the company.
• The company has a liability of $2,819,196 related to the litigation funding agreement.

Related Party Transactions

• The company has note agreements with two individuals who are related parties (a director and the Executive Chairman).
• The company has a long-term note payable with a shareholder.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and financial challenges.
• Employees may be impacted by the company's cost reduction plans and potential restructuring.
• Customers of NewStem may be impacted by the company's financial instability.
• Creditors face risk due to the company's high debt levels and uncertain future.

Next Steps

• The company needs to secure additional funding to continue operations.
• The company needs to resolve the default of the Purchase Agreement with NewStem.
• The company needs to improve its internal controls over financial reporting.
• The company needs to continue to develop and commercialize NewStem's products.
• The company needs to explore options to monetize its investment in NetCo.

Key Dates

Keywords

NovelStem International Corp, NewStem Ltd, NetCo Partners, biotech, litigation funding, going concern, financial results, equity method investment, debt financing, internal control, shareholders deficit